05.05.2025
Egnach, May 5, 2025 – The recently published results of the Apple Hearing Study reveal an alarmingly high prevalence of tinnitus: Over 77% of participants reported having suffered from ringing in the ears at some point in their lives. Approximately 15% even experience the symptoms daily. While Apple’s study draws attention to the social relevance of the problem, the therapeutic solution remains exclusive to Resaphene Suisse AG with its patented medical device tinniwell.
tinniwell: Unique therapy instead of mere background noise
“Apple has provided important data with the study – but not a solution,” says Anke Rauterkus, CEO of Resaphene Suisse AG. “Tinniwell is currently the only approved therapy device that not only masks tinnitus, but also treats its underlying cause – and in many cases, cures it.”
While Apple users are referred to simple noise masking, natural sounds, or mindfulness exercises, Tinniwell goes a decisive step further: The device combines individually tailored music therapy with targeted heat stimulation of the auditory nerve – based on neurological research and with clinically documented effectiveness.
Patent protection secures unique selling point
Tinniwell’s innovative therapy approach is protected by international patents. This prevents other companies – including technology giants like Apple – from offering a comparable medical solution.
“Our technology is unique. Anyone who truly wants to treat tinnitus cannot ignore Tinniwell,” says Rauterkus. “We welcome Apple’s raising awareness of tinnitus – but we have already developed the solution and made it available worldwide.”
Demand is rising globally
Resaphene Suisse AG has observed a significant increase in demand following the publication of the Apple data. More and more patients are seeking real therapies rather than mere symptom relief. Tinniwell is CE-certified, non-invasive, and already successfully used in several European countries. Market launches in the US and Asia are in preparation.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 71 510 07 24
a.rauterkus@resaphene.ch
Back